RiboX Secures FDA IND Clearance for World's First Circular RNA-Based In Vivo CAR-T Therapy

RiboX has secured FDA Investigational New Drug (IND) clearance for RXIM002, the world's first circular RNA-based in vivo CAR-T therapy using targeted lipid nanoparticle delivery for autoimmune cytopenias, enabling Phase I clinical development in the United States.

This Wire brief sits within Fusion42's coverage of Biotech.